Drug intelligence / Profile preview

STT-001

Development stage: Preclinical
Lead developer: STCube
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

STT-001 is a preclinical-stage monoclonal antibody developed by STCube & Company that targets Programmed Death-Ligand 1 (PD-L1). As an immune checkpoint inhibitor, STT-001 is designed to block the interaction between PD-L1, which is often overexpressed on the surface of tumor cells, and the PD-1 receptor on T cells. This blockade prevents the suppression of T-cell activity, thereby restoring and enhancing the body's natural anti-tumor immune response. The drug is currently being investigated for its potential in treating various solid tumors, with a primary focus on lung cancer and bladder cancer.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on STT-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STT-001.

Explore the full profile